European Archives - Page 963 of 1138 - European Medical Journal

Bluebird Bio and Apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

USA and Germany, December 15, 2016 – bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene…

First Data on Rare Sarcomas in Asian Patients Presented at ESMO Asia in Singapore

Lugano-Singapore, December 17, 2016 – The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016…

New Autoimmune Mutation Found in Enteritis Pathogenesis

NOVEL immunotherapy has successfully ameliorated the symptoms of autoimmune enteritis following the discovery of a genetic mutation within an immune…

Discovery Could Lead to New Treatments for Parkinson’s Disease

A BIOLOGICAL link has been discovered between the gut microbiome and Parkinson’s disease (PD), potentially leading to the development of new…

Current Percutaneous Management of Coronary Bifurcation Disease

Coronary bifurcation disease (CBD) is frequently found in patients undergoing coronary interventions. Optimal management of CBD is technically demanding…

Transcatheter Aortic Valve Implantation: Review of Current Indications, Approaches, Future Insights, and Alternatives

The use of transcatheter aortic valve implantation is increasing worldwide, with rapid development of new generations of valves and the search for…

Epigenetic Mechanisms in Sjögren’s Syndrome

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune epithelitis and recent advances in our comprehension of its pathophysiology strongly suggest a…

EMJ

EMJ Weekly News Round-Up: 12th December

Keeping you up to date with the latest news, summarising a selection of stories from us here at EMJ and from across the web.

Prognostic Models Predict Survival in Cancer Patients Receiving Palliative Care

THE FINDINGS of a new study have identified a group of prognostic models with a good ability to predict survival in cancer patients receiving…

RedHill Biopharma Announces Positive and Unanimous DSMB Recommendation for Continuation of Phase III Study with RHB-104 for Crohn’s Disease

Israel, December 13, 2016 – RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily…